Both clinical trials and animal studies show that externally administered IGF-1 can reduce neural damage while improving motor and cognitive functions, underscoring its therapeutic potential for neurodegenerative disorders such as epilepsy (Ge et al., 2022; Bhalla et al., 2022). The gene discussed is IGF1; the disease is epilepsy.